Evotec SE (EVO) Income from Non-Controlling Interests (2009 - 2019)

Evotec SE (EVO) posted Income from Non-Controlling Interests of -$933956.4 for Q4 2019, down 169684.9% sequentially from -$550.08 in Q3 2010.

Evotec SE (EVO) Income from Non-Controlling Interests (2009 - 2019) Analysis & Trends

Evotec SE has reported Income from Non-Controlling Interests for 3 years, with the latest figure at -$933956.4 in Q4 2019.

Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$933956.4 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was -$934255.1 (changed N/A YoY) and the FY2019 annual result came in at -$945219.1, changed N/A from the prior year.
Income from Non-Controlling Interests eased to -$933956.4 in Q4 2019 per EVO's latest filing, from -$550.08 in the prior quarter.
Over five years, Income from Non-Controlling Interests peaked at -$933956.4 in Q4 2019 and troughed at -$933956.4 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inc. Minority (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.15 Bn	39.49 Bn	2.15 Bn	-
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.58 Bn	22.78 Bn	5.10 Bn	376,434.15
5	United Therapeutics	22.16 Bn	19.50 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.48 Bn	15.09 Bn	935.80 Mn	-
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	-
10	Evotec SE	681.90 Mn	681.42 Mn	-	-

Download Data